PRODUCT MONOGRAPH

CLARITIN® LIQUID CAPSULES
Loratadine Capsules, 10 mg
Histamine H₁ receptor antagonist
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3
  SUMMARY PRODUCT INFORMATION ................................................................. 3
  INDICATIONS AND CLINICAL USE ................................................................. 3
  CONTRAINDICATIONS ...................................................................................... 3
  WARNINGS AND PRECAUTIONS ................................................................. 3
  ADVERSE REACTIONS ..................................................................................... 4
  DRUG INTERACTIONS ...................................................................................... 5
  DOSAGE AND ADMINISTRATION ................................................................. 6
  OVERDOSAGE ................................................................................................. 6
  ACTION AND CLINICAL PHARMACOLOGY .................................................... 6
  STORAGE AND STABILITY ........................................................................... 7
  SPECIAL HANDLING INSTRUCTIONS ........................................................... 7
  DOSAGE FORMS, COMPOSITION AND PACKAGING ................................. 7

PART II: SCIENTIFIC INFORMATION .....................................................................9
  PHARMACEUTICAL INFORMATION ............................................................... 9
  CLINICAL TRIALS .......................................................................................... 10
  DETAILED PHARMACOLOGY ....................................................................... 11
  MICROBIOLOGY ............................................................................................. 14
  TOXICOLOGY .................................................................................................. 14
  REFERENCES .................................................................................................. 18

PART III: CONSUMER INFORMATION .................................................................19
SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Capsules / 10 mg</td>
<td>For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

CLARITIN LIQUID CAPSULES (loratadine capsules, 10mg) are indicated for:
- the relief of symptoms associated with seasonal and perennial allergic rhinitis, such as sneezing, nasal discharge and itching, and ocular itching and burning.
- the relief of symptoms and signs of chronic urticaria and other allergic dermatologic disorders.

Clinical studies to date support treatment for up to six months, thus medical recommendation is advised for longer-term use.

Loratadine is not recommended for pregnant or lactating women.

Geriatrics:
The pharmacokinetic parameters of loratadine and its major metabolite are comparable in healthy adult volunteers and healthy geriatric volunteers. (See DETAILED PHARMACOLOGY I Pharmacokinetics and Metabolism).

CONTRAINDICATIONS
- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

WARNINGS AND PRECAUTIONS

Hepatic/Biliary/Pancreatic
Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine; a dose of 10 mg every other day is recommended.
**Special Populations**

**Pregnant Women:** The safe use of loratadine during pregnancy has not been established and is therefore not recommended.

**Nursing Women:** The safe use of loratadine during lactation has not been established and is therefore not recommended. (See DETAILED PHARMACOLOGY I Human Pharmacology for information on secretion into breast milk).

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**
Adverse experiences reported with CLARITIN in adults during clinical trials were mild and consisted of fatigue, headache, dry mouth, sedation, gastrointestinal disorders such as nausea, gastritis, and also allergic symptoms like rash.

Nervousness and hyperkinesia were among the reported adverse experiences in pediatric patients. Gastrointestinal adverse reactions reported during pediatric trials may have been slightly more frequent in the younger patients (less than or equal to 30 kg).

During the marketing of loratadine, alopecia, anaphylaxis, abnormal hepatic function, dizziness, palpitations and tachycardia have been reported rarely.

**Clinical Trial Adverse Drug Reactions**
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

**Claritin Tablets**

**Table 1: CLARITIN Tablets, 10 mg Once Daily vs. Placebo and Comparatives**
Number (%) of Adult Patients Reporting Frequently Occurring (>2% of loratadine treated patients) Adverse Experiences in Adults Possibly or Probably Related to Treatment: Patients Treated with CLARITIN, Placebo and Comparatives

<table>
<thead>
<tr>
<th>Loratadine 10mg QD</th>
<th>Placebo</th>
<th>Clemastine 1 mg BID</th>
<th>Terfenadine 60 mg BID</th>
<th>Astemizole 10 mg OD</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 1241</td>
<td>n = 1652</td>
<td>n = 687</td>
<td>n = 506</td>
<td>n = 342</td>
</tr>
<tr>
<td>Fatigue 54(4)</td>
<td>62(4)</td>
<td>62(9)</td>
<td>17(3)</td>
<td>22(6)</td>
</tr>
<tr>
<td>Headache 97(8)</td>
<td>104(6)</td>
<td>32(5)</td>
<td>40(8)</td>
<td>26(7)</td>
</tr>
<tr>
<td>Dry Mouth 49(4)</td>
<td>32(2)</td>
<td>22(3)</td>
<td>15(3)</td>
<td>2(1)</td>
</tr>
<tr>
<td>Dryness in Nose</td>
<td>9(&lt;1)</td>
<td>-</td>
<td>6(&lt;1)</td>
<td>3(&lt;1)</td>
</tr>
<tr>
<td>Sedation* 99(8)</td>
<td>101(6)</td>
<td>151(22)</td>
<td>41(8)</td>
<td>50(15)</td>
</tr>
</tbody>
</table>

*Reported as somnolence, sleepiness, drowsiness, lethargy, slow or “drugged feeling”
Adverse experiences reported with CLARITIN conventional tablets in adults during the clinical trials were mild and consisted of fatigue, headache, dry mouth, sedation, gastrointestinal disorders such as nausea, gastritis, and also allergic symptoms like rash. The incidence of sedation was similar to that of the comparative agents terfenadine, astemizole and placebo, but statistically different (p<0.01) from clemastine.

**Less Common Clinical Trial Adverse Drug Reactions (<1 %)**
In addition to those listed in Table 1, the following were reported less frequently (less than 1%): appetite increased, coughing, dizziness and palpitations.

**Abnormal Hematologic and Clinical Chemistry Findings**
Not applicable

**Post-Market Adverse Drug Reactions**
During the marketing of loratadine, in addition to the adverse events reported during clinical trials, alopecia, anaphylaxis (including angioedema), abnormal hepatic function, dizziness, palpitations and tachycardia have been reported rarely. Convulsions and seizures have been reported very rarely.

**DRUG INTERACTIONS**

**Serious Drug Interactions**
None to report

**Overview**
When administered concomitantly with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies (see DETAILED PHARMACOLOGY / Human Pharmacology).

**Drug-Drug Interactions**
Increases in plasma concentrations of loratadine have been reported after concomitant use with ketoconazole, erythromycin or cimetidine in controlled clinical trials, but without clinically significant changes (including electrocardiographic). Other drugs known to inhibit hepatic metabolism should be coadministered with caution until definitive interaction studies can be completed.

**Drug-Food Interactions**
See ACTION AND CLINICAL PHARMACOLOGY / Pharmacokinetics / Absorption.

**Drug-Herb Interactions**
*Interactions with herbs have not been established.*

**Drug-Laboratory Interactions**
Loratadine should be discontinued approximately 48 hours prior to skin testing procedures since antihistamines may prevent or diminish otherwise positive reactions to dermal reactivity indicators.

**Drug-Lifestyle Interactions**
*Interactions with lifestyle have not been established.*
DOSAGE AND ADMINISTRATION

Dosing Considerations
Patients with severe liver impairment: a dose of 10 mg every other day is recommended.

Recommended Dose and Dosage Adjustment
Adults and Children 12 years of age and over: One CLARITIN LIQUID CAPSULE, 10 mg, once daily.

OVERDOSAGE

Somnolence, tachycardia and headache have been reported with overdoses of the conventional loratadine formulation. A single acute ingestion of 160 mg produced no adverse effects.

In the event of overdosage, treatment, which should be started immediately, is symptomatic and supportive.

Consider standard measures to remove any unabsorbed drug in the stomach, such as adsorption by activated charcoal administered as a slurry with water. The administration of gastric lavage should be considered. Physiologic saline solution is the lavage solution of choice, particularly in children. In adults, tap water can be used; however, as much as possible of the amount administered should be removed before the next instillation. Saline cathartics draw water into the bowel by osmosis, and therefore, may be valuable for their action in rapid dilution of bowel content.

Loratadine is not cleared by hemodialysis to any appreciable extent. It is not known if loratadine is removed by peritoneal dialysis.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonistic activity. It exhibits a dose-related inhibition of the histamine-induced skin wheal and flare response in humans which is rapid in onset, is apparent at two hours and persists throughout the 24 hour observation period. Single oral doses up to 160 mg and repeat daily doses of 40 mg for up to 13 weeks were well tolerated with the incidence of sedation and dry mouth being no different from placebo.

Loratadine is well absorbed by all species studied and is almost totally metabolized (See DETAILED PHARMACOLOGY / Pharmacokinetics and Metabolism).

Pharmacodynamics
Loratadine has a lower affinity for central receptors than for peripheral receptors, and it does not readily penetrate into the brain tissue. (See DETAILED PHARMACOLOGY / Animal Pharmacology).

Wheal and Flare: The antihistaminic activity and dose-response profile of loratadine were evaluated in three clinical pharmacologic studies using a histamine-induced skin wheal suppression model in healthy male
volunteers. All doses were significantly more effective than placebo in suppressing the formation of histamine-induced skin wheals (See DETAILED PHARMACOLOGY / Human Pharmacology).

**Alcohol:** The ability of healthy male volunteers to concentrate was not impaired by loratadine in combination with alcohol. Loratadine did not potentiate the effects of alcohol on driving performance (See DETAILED PHARMACOLOGY / Human Pharmacology).

**Pharmacokinetics**

**Absorption:** 14C-loratadine is rapidly absorbed reaching C_max values (4.7, 10.8 and 26.1 ng/mL) at 1.5, 1.0 and 1.3 hours for the 10, 20 and 40 mg dose, respectively. The loratadine elimination half-life (T-1/2) ranged from 7.8-11.0 hours. Descarboethoxyloratadine, the major active metabolite, reached C_max values (4.0, 9.9 and 16.0 ng/mL) at 3.7, 1.5 and 2.0 hours after a dose of 10, 20 and 40 mg, respectively. Its T-1/2 ranged from 17 to 24 hours. The accumulation indices, calculated by C_max and the area under the curve (AUC) ratios did not change after the 5th day, indicating little or no accumulation of either loratadine or its metabolite after a multiple once per day dosage regimen. The T-1/2 at steady state levels for loratadine and its metabolite were 14.4 and 18.7 hours, respectively, similar to that reported following a single oral dose.

**Excretion:** Approximately 82% of the 14C-loratadine dose is excreted in the urine (40%) and faeces (42%) over a 10-day period. Approximately 27% of the dose, eliminated during the first 24 hours is present only in trace quantities in the urine. The active metabolite, descarboethoxyloratadine, represents only 0.4 to 0.6% of the administered loratadine dose.

**Special Populations and Conditions**

**Geriatrics:** The pharmacokinetic parameters of loratadine and its major metabolite are comparable in healthy adult volunteers and healthy geriatric volunteers. (See DETAILED PHARMACOLOGY / Pharmacokinetics and Metabolism)

**STORAGE AND STABILITY**

**Temperature and Moisture**
Store at room temperature 15° to 30°C. Protect from exposure to excessive moisture.

**Others**
Keep in a safe place out of reach of children.

**SPECIAL HANDLING INSTRUCTIONS**
None

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

**CLARITIN® LIQUID CAPSULES:** oval, transparent, blue gelatin capsule with a “10” logo etched across, containing 10 mg of loratadine. Available in blisters of 24, 36, and 84 capsules, packaged in a carton.
Composition:

Each capsule of CLARITIN LIQUID CAPSULES contains the following non-medicinal ingredients: triglycerides, mono- and di-glycerides, gelatin, sorbitol sorbitan solution, povidone, glycerin, polysorbate, purified water and FD&C blue.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: loratadine (INN, USAN)


(or)


Molecular formula: C_{22}H_{23}ClN_{2}O_{2}

Molecular mass: 382.88

Structural formula:

\[
\begin{align*}
\text{\includegraphics[width=0.5\textwidth]{structural_formula.png}}
\end{align*}
\]

Physicochemical properties: white to off-white powder, which melts between 132° and 137°C.
CLINICAL TRIALS

Comparative Bioavailability Studies

A double-blinded, randomized, three-period, three-treatment, three-sequence, crossover, single dose, comparative bioavailability study, conducted under fasting conditions, was performed on healthy male volunteers. The results obtained from 39 volunteers who completed the study are summarized in the following table. The rate and extent of absorption of loratadine was measured and compared following a single oral dose (2 x 10 mg) of Claritin® (loratadine) Tablets and Claritin® Liquid Capsules (loratadine).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Test ( ^{\text{¥}} )</th>
<th>Reference ( ^{\text{†}} )</th>
<th>Ratio of Geometric Means (%)</th>
<th>90% Confidence Interval (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUCT (ng•h/mL)</td>
<td>26.923 (42.707 (90.962))</td>
<td>25.286 (36.284 (79.264))</td>
<td>106.47</td>
<td>96.38 – 117.62</td>
</tr>
<tr>
<td>AUCI (ng•h/mL)</td>
<td>28.268 (45.217 (92.587))</td>
<td>26.418 (38.264 (80.610))</td>
<td>107.00</td>
<td>97.06 – 117.96</td>
</tr>
<tr>
<td>C(_{\text{max}}) (ng/mL)</td>
<td>7.409 (10.850 (75.548))</td>
<td>7.765 (10.370 (65.453))</td>
<td>95.42</td>
<td>84.12 – 108.24</td>
</tr>
<tr>
<td>(T_{\text{max}}) (h)</td>
<td>1.250 (0.750 – 2.667)</td>
<td>1.250 (0.750 – 2.667)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T_{\text{1/2}}) (h)</td>
<td>17.367 (41.220)</td>
<td>16.241 (43.362)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{\text{¥}}\) Claritin Liquid Capsules 10 mg

\(^{\text{†}}\) Claritin® 10 mg tablets

\(^{\text{§}}\) Expressed as Median (Range).

\(^{\text{€}}\) Expressed as Arithmetic Mean (CV\%) only.

A double-blinded, randomized, three-period, three-treatment, three-sequence, crossover, single dose, comparative bioavailability study, conducted under fed conditions, was performed on healthy male volunteers. The results obtained from 28 volunteers who completed the study are summarized in the following table. The rate and extent of absorption of loratadine was measured and compared following a single oral dose (2 x 10 mg) of Claritin® (loratadine) Tablets and Claritin®(loratadine) Liquid Capsules.
### Summary Table of the Comparative Bioavailability Data

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Test (µg/mL)</th>
<th>Reference (µg/mL)</th>
<th>Ratio of Geometric Means (%)</th>
<th>90% Confidence Interval (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC_T (ng•h/mL)</td>
<td>33.573 (91.312)</td>
<td>32.345 (87.862)</td>
<td>103.80</td>
<td>94.97 – 113.44</td>
</tr>
<tr>
<td>AUC_l (ng•h/mL)</td>
<td>35.258 (93.381)</td>
<td>33.754 (90.184)</td>
<td>104.46</td>
<td>95.57 – 114.17</td>
</tr>
<tr>
<td>C_max (ng/mL)</td>
<td>5.981 (81.665)</td>
<td>7.184 (69.881)</td>
<td>83.25</td>
<td>70.67 – 98.08</td>
</tr>
<tr>
<td>T_max (h)</td>
<td>3.617 (0.667 – 6.000)</td>
<td>2.834 (0.667 – 4.500)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T_1/2 (h)</td>
<td>16.354 (31.903)</td>
<td>16.055 (30.690)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- Test: Claritin® Liquid Capsules 10 mg
- Reference: Claritin® 10 mg Tablets
- Expressed as Median (Range)
- Expressed as Arithmetic Mean (CV%) only.

---

### DETAILED PHARMACOLOGY

#### Animal Pharmacology:

Loratadine is an orally effective antihistamine in both mice and guinea pigs. The oral PD_{50}^{*} value for preventing histamine-induced lethality in guinea pigs is 0.19 mg/kg for loratadine compared to 0.009 mg/kg for azatadine (which of the marketed antihistamines is most closely related in structure to loratadine), and 0.15 mg/kg for chlorpheniramine. In terms of duration of antihistamine action, loratadine at twice its antihistamine PD_{50} (0.5 mg/kg) is longer acting (duration: 18-24 hours) than an equi-effective dose of azatadine (duration 8-12 hours). For preventing histamine-induced paw edema in mice, loratadine has an oral PD_{50} value of 1.3 mg/kg compared to 0.068 mg/kg for azatadine and 9.6 mg/kg for chlorpheniramine. On the basis of these two tests of antihistamine activity, loratadine is at least equipotent to chlorpheniramine but less potent than azatadine. Loratadine also exhibited antihistamine activity when tested in vitro against histamine-induced contraction of the guinea pig ileum. In this test, loratadine (pA_2^f: 7.3) was less potent than azatadine (pA_2: 9.1) or chlorpheniramine (pA_2: 9.6).

---

* Dose that provides protection in 50% of animals tested.

^ pA = the negative logarithm of the concentration of the antagonist
Because there is no single laboratory test which itself can be considered predictive of the sedating effects of antihistamines, a multidimensional approach was used to assess the CNS activity of loratadine with several standard antihistamines.

In contrast to the standards, loratadine had only weak or no CNS activity in mice, rats, dogs and monkeys after oral administration. These observations included: a lack of effect vs. acetic acid writhing and electroconvulsive shock (ECS) seizures in mice at doses up to 320 mg/kg, no overt behavioral, neurologic or autonomic effects in mice or rats after doses of 10-300 mg/kg, in dogs at doses of 15-30 mg/kg and in monkeys at doses of 30-60 mg/kg.

Ex vivo studies indicate that loratadine does not readily penetrate into the CNS. Loratadine exhibited a greater affinity for peripheral H1-receptors ($Ki$: 35 nM) than for central H1-receptors ($Ki$ - 118 nM) as determined by $^3$H-mepyramine binding inhibition at membrane receptor sites from the cerebral cortex and lungs of guinea pigs. Loratadine also had no effect on brain $^3$H-mepyramine binding in mice following an oral dose of 2.6 mg/kg (twice its antihistamine ED$_{50}$ in this species). In studies determining the binding inhibition of $^3$H-WB4101, an alpha-1 receptor ligand, loratadine was the weakest inhibitor (IC$_{50}$ value ranging from 13 to 64 uM) of the several standard antihistamines studied.

$^f$ $Ki$ = the dissociation constant of an enzyme inhibitor

The compound has a lower affinity for central receptors than for peripheral receptors, and it does not readily penetrate into the brain tissue.

In terms of other pharmacologic actions studied, loratadine does not have significant H2-receptor activity in vitro at concentrations up to 5x10$^{-6}$ mmol, and does not seem to inhibit norepinephrine uptake as evidenced by its lack of effect on tetrabenazine-induced ptosis in mice at oral doses of 160 or 320 mg/kg. Loratadine also did not exhibit in vivo anticholinergic activity as measured by the lack of mydriasis in mice or rats at oral doses up to 200 mg/kg, in dogs at oral doses up to 60 mg/kg and in monkeys at doses up to 90 mg/kg. Moreover, loratadine did not antagonize physostigmine-induced lethality, which is another measure of anticholinergic activity, at oral doses up to 320 mg/kg in mice.

Loratadine had no effect on blood pressure or electrocardiogram in conscious dogs after oral doses of 1, 2.5 or 10 mg/kg. At 10 mg/kg, loratadine significantly increased heart rate. Loratadine did not significantly increase heart rate in monkeys at 2.5 mg/kg, which is about 12 times the maximum projected daily human dose. Moreover, loratadine did not increase the rate of contraction of isolated guinea pig atria which suggests that it does not directly affect pacemaker activity.

Drug interaction studies in mice showed that at 80 mg/kg of loratadine (approximately 50 times its ED$_{50}$ for blocking histamine-induced paw edema), loratadine potentiated the anticonvulsant effects of diazepam.

At a high dose of 320 mg/kg, loratadine potentiated the ability of high doses of ethanol and hexobarbital to induce loss of righting reflexes. No interaction was seen with propranolol, alpha methyl dopa, cimetidine, pseudoephedrine or d-amphetamine. A nearly identical interaction profile was seen with terfenadine.

Pharmacokinetics and Metabolism: The absorption, tissue distribution, metabolism and excretion (ADME) of $^3$H- and/or $^{14}$C-loratadine were evaluated in rats, rabbits and cynomolgus monkeys after oral and intravenous administration. Biliary excretion, enterohepatic circulation and placental transfer were evaluated in rats and enzyme induction was determined in hepatic microsomes of rats. In man, the
pharmacokinetic and metabolic disposition of $^3$H- and $^{14}$C-loratadine was investigated in healthy normal volunteers, following single and multiple oral doses.

Loratadine is well absorbed by all species studied and is almost totally metabolized. First pass metabolism is extensive. The time to maximum plasma concentration was shortest in rats (0.5 hours) and longest in monkeys (3.3 hours) while normal volunteers exhibited a $T_{\text{max}}$ of 1.1 hours.

The plasma half-life of loratadine varies between species; the shortest half-life (14.0 hours) occurs in the rat and the longest in man. The half-life of the major metabolite, descarboethoxyloratadine, could not be determined in animal species. The pharmacokinetic parameters of loratadine and its major metabolite are comparable in healthy adult volunteers and healthy geriatric volunteers. Steady-state levels of loratadine are reached after the fifth 40 mg daily dose.

In rats, given $^{14}$C-loratadine, loratadine and its metabolites are widely distributed throughout the tissues examined. Concentrations of radioactivity are highest in lungs, liver, kidneys, adrenals, pituitary and spleen. Lowest concentrations occur in brain. Radioactivity in all tissues decreases with time and no drug accumulation occurs in tissues with multiple dosing.

In animals, loratadine and its metabolites are excreted in urine (largely during the first 24 hours) and feces, after drug administration. In animals, a larger portion of the loratadine dose is excreted into the feces than into urine. In man, approximately 40% of the dose is excreted in the urine and 42% in feces over a 10-day period. Approximately 27% of the dose is eliminated in the urine during the first 24 hours.

In rats, loratadine and its metabolites undergo enterohepatic circulation. The radioactivity is eliminated in the gastrointestinal tract via the biliary route (major) and direct passage through the gastrointestinal mucosa (minor).

In pregnant rats, $^{14}$C-loratadine crosses the placental barrier both at the end of embryonic formation (day 14 of pregnancy) and at near-term (day 20 of pregnancy). At 20 days, the tissue distribution pattern in fetuses is similar to that in dams; however, the concentrations of radioactivity in fetal tissues are considerably lower than the concentrations in corresponding maternal tissues. The radioactivity disappears with time from both fetuses and dams and does not accumulate in fetal tissues.

The metabolic profiles of loratadine in fetal and maternal plasma are similar.

Enzyme induction studies with high doses demonstrate that loratadine is only a weak inducer of hepatic drug metabolizing enzyme systems in rats. Results from plasma protein binding studies revealed that loratadine is highly bound (97% to 99% in man, 98% to 99% in rat and 96% to 99% in monkey) and its active metabolite moderately bound (73% to 76% in man, 70% to 71% in rat and monkey) to human and animal plasma proteins.

**Human Pharmacology:**

Suppression of Histamine-Induced Skin Wheals: The antihistaminic activity and dose-response profile of loratadine were evaluated in three clinical pharmacologic studies using a histamine-induced skin wheal suppression model in healthy male volunteers.

Two randomized, single-blind studies evaluated the wheal suppression effects of loratadine at single oral
doses ranging from 10 to 160 mg. At these doses, loratadine demonstrated a rapid onset of action; wheal suppression was observed within two hours of treatment. All doses were significantly more effective than placebo in suppressing the formation of histamine-induced skin wheals (p<0.05); the suppression of wheal formation by loratadine was dose related.

In a third randomized, double-blind study the suppressant effects of loratadine on histamine-induced wheal formation were measured at doses ranging from 10 to 40 mg administered orally twice daily (b.i.d.) for 28 days. Wheal suppression was observed at two hours after the first dose, and by four hours, each of the four active treatments (loratadine 10 mg, 20 mg, & 40 mg and chlorpheniramine 12 mg) caused a significantly greater suppression of the wheal formation than placebo (p<0.05); this effect remained consistent over the entire 28 day study period.

In a comparative study of loratadine syrup, terfenadine suspension and placebo in reducing histamine-induced wheals and flares, single doses of 10 mg loratadine syrup and 60 mg terfenadine suspension were comparable in reducing histamine-induced wheals and flares and both were significantly more effective than placebo.

Loratadine and Alcohol:

Special tests were designed to assess the effects of loratadine either alone or in combination with alcohol on driving and psychomotor performance. In a double-blind study, the ability of healthy male volunteers to concentrate, as measured by multiple choice reactions and visuomotor coordination tests was not impaired by either 40 mg loratadine alone or in combination with 0.75 g/kg of alcohol. In another double-blind study on driving performance, 10 or 20 mg loratadine and placebo were without effect while 10 mg triprolidine significantly impaired performance. Furthermore, after ingestion of alcohol in quantities of 1.07 g/kg of lean body weight, a second test demonstrated that loratadine did not potentiate the effects of alcohol on driving performance.

Loratadine and Nursing Mothers

Loratadine and its active metabolite are eliminated in the breast milk of lactating women with milk concentrations being similar to plasma concentrations. Through 48 hours after dosing, only 0.029% of the loratadine dose is eliminated in the milk as unchanged loratadine and its active metabolite, descarboethoxyloratadine (DCL).

MICROBIOLOGY
Not applicable

TOXICOLOGY

Acute Toxicity

The oral LD<sub>50</sub>s were estimated to be greater than 5000 mg/kg in both species. In mice intraperitoneal LD<sub>50</sub> values were calculated to be 1601 and 1458 mg/kg for males and females, respectively. In male and female rats, the intraperitoneal LD<sub>50</sub> values were determined to be 5134 and 2908 mg/kg respectively. Rising single doses up to 1280 mg/kg were relatively well tolerated in monkeys with emesis at this high dose precluding the determination of acute lethal levels.
Table 2: Acute Oral Toxicity of Loratadine in Young Animals

<table>
<thead>
<tr>
<th>Species</th>
<th>Sex</th>
<th>LD₅₀ Value* mg/kg</th>
<th>Maximum Asymptomatic mg/kg</th>
<th>Maximum Non Lethal mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat [7 day old]</td>
<td>M</td>
<td>125-200⁰a</td>
<td>&lt;125</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>191</td>
<td>&lt;125</td>
<td>125b</td>
</tr>
<tr>
<td>Rat [30 day old]</td>
<td>M</td>
<td>5734</td>
<td>1580</td>
<td>2000</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>[4020 → 10,000]</td>
<td>&lt;1580</td>
<td>1580c</td>
</tr>
<tr>
<td>Monkey [7-15 mos]</td>
<td>M&amp;F</td>
<td>---</td>
<td>100</td>
<td>&gt;200</td>
</tr>
</tbody>
</table>
* 95% fiducial limits

a LD₅₀ value could not be calculated due to the distribution of the data.
b One of 10 pups died at this dose, but no signs of toxicity were observed, suggesting that the death may not have been compound-related.
c Although 1 of 10 rats died at this dose, no deaths occurred at 2000 mg/kg.

Results of studies of loratadine in adult animals suggest that there are no significant differences in acute toxicity between adults and juvenile rats or young monkeys. Repeated dose studies in young rats for one month and young monkeys for three months indicate that loratadine was well tolerated when given in a suspension up to 25 mg/kg for rats and up to 24 mg/kg for monkeys.

Plasma concentrations of loratadine from monkeys indicated that absorption of loratadine was dose-related with no trend toward accumulation during the three-month dosing period.

Intermediate-Term Studies

Table 3: Repeated Dose Studies

<table>
<thead>
<tr>
<th>Species/Type/No. Used</th>
<th>Duration of Study</th>
<th>Dosage mg/kg (once daily)</th>
<th>Method and Vehicle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rats, 10/sex/group</td>
<td>2 weeks</td>
<td>15, 60, 240</td>
<td>gavage, 0.25% aqueous methylcellulose</td>
</tr>
<tr>
<td>Rats, 15 or 20/group</td>
<td>3 months</td>
<td>8, 32, 128</td>
<td>gavage, 0.4% methylcellulose</td>
</tr>
<tr>
<td>Rats, 15/sex/group</td>
<td>6 months</td>
<td>4, 16, 72</td>
<td>In diet</td>
</tr>
<tr>
<td>Monkeys, 4 or 6/sex/group</td>
<td>3 months</td>
<td>8, 24, 72</td>
<td>gavage, 0.4% aqueous methylcellulose</td>
</tr>
<tr>
<td>Monkeys, 6/sex/group</td>
<td>3 months</td>
<td>0.4, 1.2, 2.4</td>
<td>gavage, 0.4% aqueous methylcellulose</td>
</tr>
<tr>
<td>Monkeys, 4/sex/group</td>
<td>6 months</td>
<td>4, 16, 72</td>
<td>gavage, 0.4% aqueous methylcellulose</td>
</tr>
</tbody>
</table>

Charles River CD Type rats or cynomolgus monkeys were used. All groups had similar controls and were given the vehicle or diet alone.
Rats were more sensitive than monkeys to the effects of loratadine; females more sensitive than males. Anticholinergic effects, evidence by reduced fecal excretion and/or mydriasis were observed in both species. In long-term studies, anticholinergic effects were apparent in rats at a dose of 128 mg/kg/day or greater; in monkeys such effects were observed at a dose of 16 mg/kg/day. Phospholipidosis was also observed; the incidence and severity were dose related and were more pronounced in the rat. Minimal signs of phospholipidosis were observed in rats at a dose of 8 mg/kg/day; in monkeys evidence was apparent at 4 mg/kg/day or more. The degree of phospholipidosis did not interfere with cellular function, appeared to lessen over time and appeared to be reversible. No evidence of phospholipidosis was observed in man following treatment with 40 mg/kg for three months. Other compounds currently in therapeutic use (e.g. imipramine and chlorphentermine) which are amphiphilic as is loratadine, have been reported to produce phospholipidosis in animals. Prolongation of QRS-interval was observed in monkeys at a dose 200 times the proposed clinical dose. The quinidine-like effect is commonly seen with antihistamines and is not associated with significant clinical effects.

**Long-Term Toxicity Studies**

During long-term toxicity studies conducted in mice, rats and monkeys, changes were observed in reproductive organs of male rats, consisting of weight reduction of the prostate gland and the testes; those changes were without consequence after a recovery period of 28 days. Similar changes in the male rat have been observed after administering drugs like antazoline, dexchlorpheniramine, meclizine, phenbenzamine and pyribenzamine.

**Table 4: Long-term Toxicity Studies**

<table>
<thead>
<tr>
<th>Species</th>
<th>Duration</th>
<th>Loratadine Dosage mg/kg/day</th>
<th>Vehicle and Method Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>12 mos</td>
<td>0.2 0.5 1.0</td>
<td>Diet oral</td>
</tr>
<tr>
<td></td>
<td>12 mos</td>
<td>2 8 32</td>
<td>Diet oral</td>
</tr>
<tr>
<td></td>
<td>24 mos</td>
<td>4 10 25</td>
<td>Diet oral</td>
</tr>
<tr>
<td>Mouse</td>
<td>18 mos</td>
<td>4 12 40</td>
<td>Diet oral</td>
</tr>
<tr>
<td>Monkey</td>
<td>17 mos</td>
<td>4 12 40 0.4% methylcellulose; esophageal intubation</td>
<td></td>
</tr>
</tbody>
</table>

**Mutagenicity Studies**

In five distinctly different genetic toxicity assays designed to detect the major types of genotoxicity i.e. Ames test, Mouse Lymphoma, Chinese Hamster Ovary, Human Lymphocyte and the Mouse Micronucleus Assays, the only activity elicited by loratadine was observed in the nonactivation phase of the mouse lymphoma assay. This activity was not dose-related.

**Reproduction Studies**

Loratadine was not teratogenic in rats or rabbits. In rats, decreased fertility was observed at the highest dose tested, approximately 320 times the proposed clinical dose. Subsequent matings within this segment
of the reproduction studies demonstrated this effect to be readily reversible. Other pregnancy parameters (pregnancy rate, litter size, number of implantations, corpora lutea) were not affected at doses approximately 40-120 times the anticipated clinical dose. Effects on these parameters above these dose levels were generally related to the pharmacodynamic activity of loratadine, and have been reported to be associated with other antihistamines.

**Mucous membrane irritation study**

No evidence of mucous membrane irritation was observed after daily administration of up to 12 tablets (120 mg) of loratadine into the hamster cheek pouch for five days.
REFERENCES


2. Data on file, Schering-Plough Canada Inc., Kirkland (Quebec).


PART III: CONSUMER INFORMATION

CLARITIN® LIQUID CAPSULES
Loratadine Capsules, 10 mg

This leaflet is part III of a three-part "Product Monograph" published when CLARITIN LIQUID CAPSULES was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about LORATADINE LIQUID CAPSULES. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
CLARITIN LIQUID CAPSULES provide:
• fast relief from symptoms of allergies, including sneezing, runny nose and itchy nose, as well as itchy watery red eyes, caused by exposure to seasonal allergens (trees, grass, and ragweed pollen) and perennial (year round) allergens (dust mites, animal dander and moulds).
• fast relief of allergic skin conditions, such as skin itch and hives.

What it does:
CLARITIN LIQUID CAPSULES contain a long-acting antihistamine, which-blocks the action of histamine and relieves allergy symptoms. Histamine is a chemical released by the immune system – the body's defense against invading substances – when the body is affected by substances that you are allergic to (allergens).

Most people will feel relief of allergy symptoms within 2 hours of taking the medication.

Symptom relief will be maintained for 24 hours. CLARITIN LIQUID CAPSULES do not cause drowsiness. It lets you stay alert and focused while relieving allergy symptoms.

When it should not be used:
CLARITIN LIQUID CAPSULES should not be used:
• if you are allergic to loratadine or to any of the other product ingredients (see What the important non-medicinal ingredients are).
• if you are pregnant or nursing.

What the medicinal ingredient is:
Loratadine

What the important non-medicinal ingredients are:
Triglycerides, mono- and di-glycerides, gelatin, sorbitol sorbitan solution, povidone, glycerin, polysorbate, purified water and FD&C blue.

What dosage forms it comes in:
Capsules, 10 mg

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
Tell your doctor if you have or have ever had liver disease. If appropriate, your doctor may recommend that you take one capsule (10 mg) of Claritin Liquid Capsules every other day.

BEFORE taking CLARITIN LIQUID CAPSULES talk to your doctor or pharmacist if you:
• Have or have ever had liver disease
• Are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking Claritin Liquid Capsules, call your doctor.

Stop taking CLARITIN LIQUID CAPSULES 48 hours prior to any skin testing procedures.

INTERACTIONS WITH THIS MEDICATION

CLARITIN LIQUID CAPSULES may interact with other medications. Always tell your doctor and pharmacist what prescription and non-prescription medications, vitamins, nutritional supplements and herbal products you are taking. It is important to mention other cold and allergy medications you are taking.

PROPER USE OF THIS MEDICATION

Usual Dose
CLARITIN LIQUID CAPSULES: Adults and adolescents (12 years of age and older): One capsule daily, with water.

Adults and adolescents (12 years of age and older) can take this medication for up to 6 months. However, prolonged use should only be on the advice of a
physician.

**Overdose**

In Case of Overdose: call a health care practitioner, hospital emergency department or regional poison control centre immediately, even if you do not notice any signs or symptoms.

**Missed Dose:**
If you miss taking your dose on time, do not worry; take your dose when you remember. Do not exceed more than one dose in 24 hours.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Along with its desired effects CLARITIN LIQUID CAPSULES may cause undesirable effects.

Mild side effects that may occur include fatigue, headache, dry mouth, sedation, stomach and digestive discomfort such as gastritis (inflammation of the stomach) and nausea. Tell your doctor if any of these symptoms are severe or do not go away.

Uncommon side effects include: increase in appetite, coughing, and dizziness. Rarely you may experience allergic reactions to the medication that may appear as a rash, swelling or difficulty in breathing, wheezing, swelling of the eyes, face, lips, tongue, throat. Additionally, hair loss, abnormal liver function, and abnormally fast heart rate or heart palpitations may occur rarely. Convulsions and seizures may occur very rarely.

<table>
<thead>
<tr>
<th>Common</th>
<th>Talk to your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking CLARITIN LIQUID CAPSULES, contact your doctor or pharmacist.

**HOW TO STORE IT**

Store at room temperature 15° to 30°C. Protect from exposure to excessive moisture.

Keep out of reach of children.
REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

• Report online at www.healthcanada.gc.ca/medeffect
• Call toll-free at 1-866-234-2345
• Complete a Canada Vigilance Reporting Form and:
  o Fax toll-free to 1-866-678-6789, or
  o Mail to:  Canada Vigilance Program
               Health Canada
               Postal Locator 0701E
               Ottawa, Ontario
               K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting the sponsor, Bayer Inc., Consumer Care at: 1 866 241-3891.

This leaflet was prepared by Bayer Inc., Consumer Care, Mississauga, ON, L4W 5R6.

Last revised: December 04, 2014